Akums Drugs & Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,342 Cr +31.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
AD

Akums Drugs & Pharmaceuticals Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,056Cr
+11.9% YoY
+4.6% QoQ
Net profit
₹150Cr
Turned profitable YoY
+127.3% QoQ
Margin
9%
+8.7 pp YoY
−3 pp QoQ

Akums Drugs & Pharmaceuticals Ltd Q4 FY25 key numbers

Revenue
Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth.

As stated in Akums Drugs & Pharmaceuticals Ltd's Q4 FY25 earnings call transcript · published 6 Aug 2026. Reported figures, not investment advice.

Price₹750
Market cap₹11.4K Cr
P/E37.5

The short version

Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. Revenue Growth: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%).

From Akums Drugs & Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth.
  • Domestic Formulations: Targeting double-digit top-line growth, higher than overall Indian pharma market growth of around 8-9%.
  • CDMO Business: Expecting at least 20% year-on-year growth in current export and CDMO business. Volume growth targeted in single high digits (~9% QoQ currently), with revenues dependent on volatile API prices.
  • Export Business: Base branded export business expected to grow at high double digits (~20%+) over next 2-3 years.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex.
  • Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms.
  • EUR 20 million (approx. INR 160+ crores) planned for plant upgrades and dossier development to meet European GMP standards for a large 6-year European contract.
  • New product facility being set up at Baddi 1 (A 11) for serving European markets.
  • Strategy includes adding capacity with foresight of 24 months due to plant validation timelines.
  • Capacity expansions are spread across dosage forms, including injectables, oral solids, oral liquids, oncologics, and steroids.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Akums Drugs & Pharmaceuticals has a significant contract in Europe valued at EUR100 million (~INR950 crores part payment received on April 9, 2025).
  • This contract is structured as a 6-year deal, expected to generate roughly INR300-350 crores in annual revenue.
  • The European contract marks entry into about 20 countries.

2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Akums Drugs & Pharmaceuticals Ltd Q4 FY25 results — key figures

Akums Drugs & Pharmaceuticals Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue1,056944+11.9%1,010+4.6%
Operating profit (EBITDA)943+3033.3%121-22.3%
Operating margin9%0.3%+8.7 pp12%-3 pp
Profit before tax75-33—91-17.6%
Net profit (PAT)150-39—66+127.3%
EPS (₹)9.38-2.89—4.14+126.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Akums Drugs & Pharmaceuticals Ltd Q4 FY25 results?

Trade Generics: Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. Revenue Growth: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%).

What is Akums Drugs & Pharmaceuticals Ltd share price analysis?

Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.

Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?

FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex. - Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms. - EUR 20 million (approx.

Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.